Kanglitai Pharmaceutical

Anhui Kanglitai Pharmaceutical is a clinical-stage biopharmaceutical company based in Hefei, China, specializing in the development of innovative cytokine-based immunotherapies. The company's core expertise lies in recombinant protein engineering and large-scale production, with a primary focus on its lead candidate, KLT-101 (recombinant human interleukin-12). Kanglitai is advancing its pipeline to address high-need indications including various solid tumors, chronic hepatitis B, and hematopoietic acute radiation syndrome. The firm operates an integrated R&D and manufacturing facility that complies with GMP standards to support its clinical and future commercial needs. By leveraging its proprietary protein platform, Kanglitai aims to provide effective biological treatments for patients with cancer and infectious diseases.